Vincerx Pharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vincerx Pharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q1 | 2025 | Mar 31, 2025 | ($5.00M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2024 | ($7.84M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2024 | ($1.81M) | Aug 8, 2024 |
| Q1 | 2025 | Mar 31, 2024 | ($12.43M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.01M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.55M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.65M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.88M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($18.42M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($16.42M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($24.52M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($2.03M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.28M) | May 12, 2022 |
| Q1 | 2021 | Sep 30, 2020 | ($434.3K) | Nov 10, 2020 |
| Q3 | 2021 | Sep 30, 2020 | ($307.0K) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($33.0K) | Aug 12, 2021 |
| Q3 | 2020 | Mar 31, 2020 | ($11.5K) | May 6, 2020 |
| Q1 | 2021 | Mar 31, 2020 | ($4.0K) | May 17, 2021 |
| Q3 | 2020 | Dec 31, 2019 | ($435) | May 6, 2020 |
| Q3 | 2020 | Sep 30, 2019 | ($100) | May 6, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q1 | 2025 | Mar 31, 2025 | ($3.33M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2024 | ($7.79M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2024 | ($7.37M) | Aug 8, 2024 |
| Q1 | 2025 | Mar 31, 2024 | ($7.48M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.61M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($12.06M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($15.41M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.90M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($19.62M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($21.63M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($17.93M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($17.39M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($9.63M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($305.0K) | Nov 12, 2021 |
| Q1 | 2021 | Sep 30, 2020 | ($440.4K) | Nov 10, 2020 |
| Q2 | 2021 | Jun 30, 2020 | ($33.0K) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($4.0K) | May 17, 2021 |
| Q3 | 2020 | Mar 31, 2020 | ($38.6K) | May 6, 2020 |
| Q1 | 2021 | Sep 30, 2019 | ($100) | Nov 10, 2020 |
| Q3 | 2020 | Mar 31, 2019 | ($1.5K) | May 6, 2020 |